Winter Elizabeth M, van Oorschot Angelique A M, Hogers Bianca, van der Graaf Linda M, Doevendans Pieter A, Poelmann Robert E, Atsma Douwe E, Gittenberger-de Groot Adriana C, Goumans Marie Jose
Departments of Anatomy and Embryology, Molecular Cell Biology, and Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Circ Heart Fail. 2009 Nov;2(6):643-53. doi: 10.1161/CIRCHEARTFAILURE.108.843722. Epub 2009 Aug 6.
Adult human epicardium-derived cells (EPDCs), transplanted into the infarcted heart, are known to improve cardiac function, mainly through paracrine protection of the surrounding tissue. We hypothesized that this effect might be further improved if these supportive EPDCs were combined with cells that could possibly supply the ischemic heart with new cardiomyocytes. Therefore, we transplanted EPDCs together with cardiomyocyte progenitor cells that can generate mature cardiomyocytes in vitro.
EPDCs and cardiomyocyte progenitor cells were isolated from human adult atrial appendages, expanded in culture, and transplanted separately or together into the infarcted mouse myocardium (total cell number, 4x10(5)). Cardiac function was determined 6 weeks later (9.4T MRI). Coculturing increased proliferation rate and production of several growth factors, indicating a mutual effect. Cotransplantation resulted in further improvement of cardiac function compared with single cell-type recipients (P<0.05), which themselves demonstrated better function than vehicle-injected controls (P<0.05). However, in contrast to our hypothesis, no graft-derived cardiomyocytes were observed within the 6-week survival, supporting that not only EPDCs but also cardiomyocyte progenitor cells acted in a paracrine manner. Because injected cell number and degree of engraftment were similar between groups, the additional functional improvement in the cotransplantation group cannot be explained by an increased amount of secreted factors but rather by an altered type of secretion.
EPDCs and cardiomyocyte progenitor cells synergistically improve cardiac function after myocardial infarction, probably instigated by complementary paracrine actions. Our results demonstrate for the first time that synergistically acting cells hold great promise for future clinical regeneration therapy.
已知将成人来源的心外膜细胞(EPDCs)移植到梗死心脏中可改善心脏功能,主要是通过对周围组织的旁分泌保护作用。我们推测,如果将这些具有支持作用的EPDCs与可能为缺血心脏提供新心肌细胞的细胞联合使用,这种效果可能会进一步改善。因此,我们将EPDCs与能够在体外生成成熟心肌细胞的心肌祖细胞一起进行移植。
从成人心房附件中分离出EPDCs和心肌祖细胞,在培养中进行扩增,然后单独或一起移植到梗死的小鼠心肌中(细胞总数为4×10⁵)。6周后通过9.4T磁共振成像(MRI)测定心脏功能。共培养可提高增殖率并增加几种生长因子的产生,表明存在相互作用。与单细胞类型移植受体相比,联合移植导致心脏功能进一步改善(P<0.05),而单细胞类型移植受体本身的功能也优于注射赋形剂的对照组(P<0.05)。然而,与我们的假设相反,在6周的观察期内未观察到移植来源的心肌细胞,这表明不仅EPDCs,而且心肌祖细胞也以旁分泌方式发挥作用。由于各组之间注射的细胞数量和植入程度相似,联合移植组额外的功能改善不能用分泌因子数量的增加来解释,而可能是由于分泌类型的改变。
EPDCs和心肌祖细胞可协同改善心肌梗死后的心脏功能,可能是由互补的旁分泌作用所激发。我们的结果首次证明,协同作用的细胞对未来的临床再生治疗具有巨大潜力。